Why are nearly half of all recent biotech RNA alliances in Asia-Pacific betting big on oligonucleotides?
BioPharma Reporter
APRIL 30, 2024
A recent study finds RNA deals are âdominatedâ by oligonucleotides and mRNA vaccines in APAC
Marketing Regulation RNA Vaccine 
Noxopharm in-licenses novel RNA tech for drug discovery and vaccines
BioPharma Reporter
DECEMBER 6, 2021
Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.
RNA 
52
52 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pfizer/BioNTech say COVID-19 vaccine could be approved in Europe by year-end
pharmaphorum
DECEMBER 1, 2020
Pfizer and BioNTech have filed their COVID-19 vaccine with the European medicines regulator, paving the way for a potential approval before the end of the year. The filing for a conditional marketing authorisation completed the rolling submission process that began on October 6.
Vaccination 88
88 
Pfizer/BioNTech to deliver COVID-19 vaccine to UK after approval
pharmaphorum
DECEMBER 2, 2020
Pfizer and BioNTech are preparing to deliver their COVID-19 vaccine to the UK after the country’s drugs regulator became the first authority in the world to approve it. Distribution will be prioritised – the Joint Committee on Vaccine and Immunisation has already set out priority groups who will receive the vaccine.
Vaccination 88
88 
UK faces “V-Day” and largest ever vaccination programme
pharmaphorum
DECEMBER 7, 2020
Tuesday has been dubbed “V-day” in the UK, when the first doses of Pfizer/BioNTech’s coronavirus vaccine will be distributed to the public outside of a clinical trial. Health secretary Matt Hancock reportedly came up with the wartime analogy to describe what will be the largest scale vaccination programme in the country’s history.
Vaccination 100
100 
Pfizer begins US pilot delivery programme for COVID-19 vaccine
pharmaphorum
NOVEMBER 17, 2020
Pfizer has begun a pilot delivery programme in the US for its experimental COVID-19 vaccine, as the company seeks to overcome logistical challenges caused by its ultra-cold storage requirements. The vaccine developed in partnership with Germany’s BioNTech has been shown to be 90% effective in clinical trials.
Vaccination 78
78 
Moderna reports mixed earnings as costs jump
BioPharma Reporter
FEBRUARY 27, 2023
The Boston-based messenger RNA (mRNA) specialist Moderna revealed $19.3bn in revenues last year, but rising costs and falling demand for its COVID-19 vaccine cut into its earnings in the fourth quarter of 2022.
RNA 103
103 
Novavax provides 1.1 billion COVID shots to global vaccine drive
pharmaphorum
FEBRUARY 19, 2021
billion doses of its COVID-19 vaccine to the COVAX global initiative led by Gavi, the vaccine alliance, which aims to ensure fair access across the globe. There are growing concerns about the lack of COVID vaccines available to poorer countries. billion COVID shots to global vaccine drive appeared first on.
Vaccination 80
80 
Sinovac raises $515m to boost production of potential COVID-19 vaccine
pharmaphorum
DECEMBER 7, 2020
China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion. Sinovac has a coronavirus vaccine in late-stage development, which is undergoing large-scale trials in Brazil, Pakistan, Indonesia and Chile. A further 1.8
Vaccination 59
59 
England begins Moderna vaccine rollout as lockdown eases
pharmaphorum
APRIL 13, 2021
England is beginning its rollout of the Moderna COVID-19 vaccine, offering an alternative to the AstraZeneca/Oxford University jab following a potential link to a very rare kind of blood clot. The Moderna shot is the third vaccine to become available in the country, which has made considerable progress with its inoculation campaign.
Vaccination 52
52 
Gritstone bio trumpets first data for ‘multivariant’ COVID jab
pharmaphorum
JANUARY 5, 2022
A COVID-19 vaccine that could work against multiple variants of the coronavirus – developed by US biotech Gritstone bio – has generated encouraging immune response data in its first clinical trial. “But it may be; and if it doesn’t other novel vaccines with similar benefits may well take on this role.”
Protein 126
126 
Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union
Pfizer
JANUARY 27, 2023
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.
Marketing 75
75 
FDA backs Moderna COVID-19 shot ahead of emergency use vote
pharmaphorum
DECEMBER 16, 2020
Moderna looks odds on to claim emergency use authorisation from the FDA for its COVID-19 vaccine this week, after the regulator published a report endorsing its safety and rating its efficacy at 94.5%. Both vaccines will be provided free of charge to recipients.
Vaccination 98
98 
Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry
Roots Analysis
OCTOBER 30, 2023
In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.
RNA 40
40 
Moderna and BioNTech – who are they?
pharmaphorum
DECEMBER 21, 2020
Moderna and BioNTech, two rising stars in biotech, were in the limelight this year with their pioneering mRNA vaccines against COVID-19. But the tragic events of 2020 have meant these companies have become household names as their trailblazing mRNA vaccines became the first to be approved by regulators against the COVID-19 scourge.
Vaccination 111
111 
CureVac : CureVac and Bayer Join Forces on COVID-19 Vaccine Candidate CVnCoV
The Pharma Data
JANUARY 6, 2021
Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. “The need for vaccines against COVID-19 is enormous. Bayer holds further options to become Marketing Authorization Holder in other markets outside of Europe.
Vaccination 52
52 
Complex Medicines: A multi-billion-pound addition to the UK life sciences industry
pharmaphorum
JULY 19, 2021
A new report published by Medicines Discovery Catapult and CPI details the huge medical and market potential for complex medicines in the UK. Over 50% identified a better understanding of complex medicines by regulators as key to developing this field. The potential for complex medicines is vast.
Life Science 52
52 
Nine for 2022: International issues that are compelling, new or changed in 2022
pharmaphorum
JANUARY 5, 2022
The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, the world’s first person to receive a COVID-19 vaccine outside clinical trials. Add to this the fact that the world missed the WHO targets for global vaccination by the end of 2021 and will likely continue to miss targets in 2022.
Vaccination 98
98 
Conversations from Cancer Research Horizons’ Innovation Summit 2023
Drug Discovery World
JANUARY 2, 2024
More significantly, she says, with the boost from what we have learned from Covid, cancer vaccines will become a reality. She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer.
Research 59
59 
World RNA Day: What impact RNA it had on drug discovery?
Drug Discovery World
AUGUST 1, 2023
1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Since then, it has been observed to publicise the importance of this molecule in the generation of proteins in the body.
RNA 52
52 
The future outlook for mRNA therapies
Drug Discovery World
APRIL 30, 2024
Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. For instance, consider how at the end of 2018, the mRNA therapies market was valued at $3.43 mRNA is a molecule made up of a single strand of ribonucleic acid (RNA).
RNA 52
52 
RNA Therapeutics: A Novel Approach to Treating Diseases
Roots Analysis
OCTOBER 22, 2023
RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.
RNA 40
40 
New RSV therapies may accelerate the emergence of resistant strains
Pharmaceutical Technology
FEBRUARY 1, 2023
Pharmaceutical companies have been working on developing vaccines and other prophylactics for respiratory syncytial virus (RSV) since its discovery in 1956. Despite strong efforts and scientific advances, a safe and effective vaccine for RSV has yet to be approved for any patient population.
Vaccination 162
162 
Biopharma Leaders Unite To Stand With Science
The Pharma Data
SEPTEMBER 8, 2020
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.
Vaccination 52
52 
Biopharma Leaders Unite To Stand With Science
The Pharma Data
SEPTEMBER 8, 2020
— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.
Vaccination 52
52 
How AI in pharma can live up to the hype
Drug Discovery World
SEPTEMBER 28, 2022
In fact, the market research firm, Bekryl, predicts that AI has the potential to offer over $70 billion in savings for the drug discovery process by 2028. . According to Hampleton Patners’ latest Healthtech M&A market report2, digital health companies raised a total of $57.2 Some recent highlights from market-leaders include: .
Social media erupts as anti-vaxxers respond to COVID-19 vaccine approval
pharmaphorum
DECEMBER 2, 2020
In the midst of the jubilation about the UK’s emergency approval of Pfizer/BioNTech’s COVID-19 shot in the UK came the depressingly inevitable round of anti-vaccine social media activity and lobbying.
Vaccination 105
105 
Will Vaccines Work Against the New Coronavirus Variants?
The Pharma Data
JANUARY 21, 2021
Because the new COVID-19 vaccines should still work on these viral interlopers. Luckily, the new variants still rely on the coronavirus’ “spike protein” to infect cells, and the two COVID vaccines now on the U.S. FRIDAY, Jan. “The spike is really critical. “I am extremely worried about the U.K.
Vaccination 52
52 
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
The Pharma Data
MARCH 4, 2021
“Ovid may benefit significantly, but without the obligation to commit the substantial capital needed over the coming years as soticlestat completes pivotal trials and, if successful, enters the global market. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Development 52
52 
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
The Pharma Data
JANUARY 21, 2021
ViiV Healthcare is the marketing authorization holder for CABENUVA. In the ATLAS study, CABENUVA met the primary endpoint for noninferiority (the proportion of participants with plasma HIV-1 RNA ?50 Two percent of patients receiving the long-acting injectable and 1% of patients receiving CAR had an HIV-1 RNA level ?50
FDA Approval 52
52 
Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel
The Pharma Data
JANUARY 4, 2021
Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. We hope to continue to see authorizations in additional markets in the coming days, weeks and months.”.
Vaccination 52
52 
Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19
Pfizer
DECEMBER 13, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. Research Vaccines. COVID-19 Research Vaccines. Antimycobacterials: rifampin. Herbal Products: St.
Drugs 110
110 
Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends
XTalks
AUGUST 2, 2023
With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations.
Sales 98
98 
Pfizer Signs Agreement to Provide the European Union with PAXLOVID™
Pfizer
NOVEMBER 23, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Pfizer has committed to provide its patent-protected medicines and vaccines available in the U.S. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor.
Licensing 40
40 
U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™
Pfizer
DECEMBER 20, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. Research Vaccines. Anticancer drugs: apalutamide. Antimycobacterials: rifampin. Herbal Products: St. 12.09.2022.
Drugs 69
69 
What to expect from PEGS Europe 2023: Day 3
Drug Discovery World
NOVEMBER 13, 2023
Next-generation immunotherapies The fourth track of PEGS Europe 2023 on the third day is ‘Next-generation immunotherapies’, which will feature a range of sessions made up of presentations, talks and posters which address cell-based immunotherapies, vaccines, and checkpoints and agonists.
Protein 59
59 
FDA gives COVID-19 vaccine ‘advice’ after White House blocks guidance
pharmaphorum
OCTOBER 7, 2020
The FDA may have been blocked from issuing stricter guidelines for emergency approval of COVID-19 vaccines by the Trump administration, but it has still managed to make its new approach public. Industry is also concerned.
Vaccination 59
59 
2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences
XTalks
DECEMBER 24, 2020
From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.
Life Science 111
111 
Which Arthritis Painkiller Works the Fastest?
The Pharma Data
MAY 13, 2021
Stimulates DNA and RNA synthesis. Carl was taking ibuprofen and opiates to manage the pain, but knew he had to be careful to regulate it because of the kidney and liver problems it could cause. Increases your energy levels by increasing ATP production. Activates and speeds up the lymphatic system.
Pharmacy 52
52 
Advances in neuroscience drug discovery
Drug Discovery World
FEBRUARY 22, 2024
But psychopharmacology developments petered out, and few new drugs reached the market during the last four decades. The report also highlights that the global neuroscience market (GNM) “was worth $612 billion in 2022 and could grow to $721 billion by 2026.
Drugs 59
59 
Covid-19 vaccine success bolsters nanoparticle drug delivery research
Pharmaceutical Technology
APRIL 24, 2023
Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages.
Drug Delivery 147
147 
COVID-19 Pandemic Coverage
XTalks
SEPTEMBER 14, 2020
“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.
Vaccination 92
92 
Let's personalize your content